Xerostomia Therapeutics Segmentation
Treatment Type (Saliva Substitutes, Salivary Stimulants, Dentifrices)
The salivary stimulants segment is anticipated to register the largest share of 42.8% in the xerostomia therapeutics market during the forecast period. The dominance of this segment is highly attributed to the continuous and rigorous occurrence of Sjögren’s syndrome among the worldwide population. In the U.S., above 3.9 million individuals are diagnosed with the disease, out of which 81.4% are reported to be severe, reflecting a sustained demand for stimulants such as pilocarpine and cevimeline. Besides, the U.S. FDA prioritized chewable cevimeline, extending its contribution for the segment’s leadership by reducing dosing frequency and improving compliance.
Drug Class (Cholinergic Agonists, Local Anti-inflammatory Agents)
The cholinergic agonists segment is projected to register considerable growth in the xerostomia therapeutics market by 2037. The growth in the segment is primarily subject to its affordability, the aging demographics, and the generic boom in emerging countries. ICMR reports in 2024 state that generic pilocarpine tablets cost USD 0.55 per dose to USD 16.5 per dose for biologics, making them the first-line therapy in emerging markets. Further, WHO projects a 5.9% CAGR in terms of agonists owing to above 490 million elderly population by 2030. Sun Pharma and CSPC Pharma control 61.7% of Asia’s pilocarpine supply with a focus on cutting prices.
Our in-depth analysis of the global xerostomia therapeutics market includes the following segments:
|
Treatment type |
|
|
Drug Class |
|
|
Distribution Channel |
|
